Proactive Investors - Run By Investors For Investors

Biomerica Inc in clinical trials for their diagnostic-guided therapy that helps identify IBS

Biomerica Inc (NASDAQ:BMRA, OTCUS:BMRA) CEO Zack Irani-Cohen tells Proactive Investors the global biomedical company that develops, manufacturers, and markets advanced diagnostic products that tells a doctor how to treat a patient.

Biomerica focuses on products for gastrointestinal disease including IBS. The Biomerica InFoods IBS product identifies patient specific foods that when removed may alleviate a patient's IBS symptoms. Irani-Cohen says Biomerica is in clinical trials for their diagnostic-guided therapy, and could be taking their product to the market in the next few years.

 
View full BMRA profile View Profile

Biomerica, Inc. Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use